News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

American College of Rheumatology: Anti-IL17 Drug Misses Endpoint in RA Trial, Stanford University Study



11/11/2010 6:12:28 AM

ATLANTA -- An investigational biologic drug with a novel target in rheumatoid arthritis failed to meet its primary endpoint in a phase II placebo-controlled trial, researchers reported here.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES